Announcement • Jul 17
Marvel Biosciences Corp. announced that it expects to receive CAD 3 million in funding Marvel Biosciences Corp. has announced non-brokered private placement to issue 20,000,000 at the price of CAD 0.15 for the gross proceeds of CAD 3,000,000 on July 16, 2026. Each warrant entitles the holder thereof to acquire one additional common share and one common share purchase warrant at an exercise price of CAD 0.20 per warrant on the sixty first day after the closing date of the offering for a period of 1 year from the date of issuance. The offering is subject to regulatory approvals, including approval from the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The Units offered under the Listed Issuer Financing Exemption will not be subject to a hold period pursuant to applicable Canadian securities laws. Shareholders or investors who may wish to participate in the Offering and who seek further details about the Offering should contact the Company’s Chief Executive Officer, J. Roderick Matheson, at 403 770 2469. In connection with the Offering, the Corporation will pay a finder’s fees equal to up to 7% of the gross proceeds raised from those investors introduced by the finder to the Offering, payable in cash, and finder’s warrants in an amount equal to 7% of the aggregate number of Units in relation to subscribers introduced by any particular finder, with each Finder’s Warrant being exercisable to acquire one Common Share at a price of CAD 0.20 per share commencing on the sixty first (61st) day after the Closing Date for a period of one year from the Closing Date provided that if, at any time after the date that is sixty-one days following the Closing Date. The closing of the Offering may occur in one or more tranches, the first of which is expected to close on or about August 14, 2026. Closing of the Offering is subject to receipt of all regulatory approvals, including approval of the TSX Venture Exchange, and will occur within 45 days from the date hereof. New Risk • Jun 22
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$779k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$779k free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-CA$2.7m). Revenue is less than US$1m. Market cap is less than US$10m (CA$12.3m market cap, or US$8.67m). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding). Announcement • Jun 10
Marvel Biosciences Corp. Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for Mb-204 Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026. The patent is expected to be granted shortly after August 28, 2026. The Australian notice of allowance further strengthens Marvel's global composition-of-matter patent portfolio for MB-204, reinforcing the Company's intellectual property position as it advances into Phase I clinical development following positive preclinical efficacy and toxicology results. Such includes recent preclinical studies in Rett syndrome models that demonstrated that MB-204 significantly outperformed the approved therapy trofinetide across multiple efficacy endpoints and produced sustained therapeutic benefits that persisted after treatment cessation, suggesting the potential for disease-modifying effects. Broadening patent protection across key pharmaceutical markets enhances the asset's commercial value by extending market exclusivity, reducing competitive risk, and increasing its attractiveness for potential licensing, partnering, and strategic investment opportunities. Marvel Biosciences Corp. has also recently filed for patents on a novel liquid-based formulation of MB-204 which should help lengthen the lifetime of its patent estate. MB-204 is a novel fluorinated analogue of the approved adenosine A2a receptor antagonist Istradefylline which is used for the treatment of Parkinson’s Disease. MB-204 has demonstrated superior pharmacokinetics and completed pre-clinical toxicology testing and has shown excellent pre-clinical efficacy studies in depression and multiple models of autism including Rett Syndrome. The compound is currently being tested in Fragile X models. Currently, around 1 in 36 children at age 8 have been diagnosed with autism spectrum disorder which underscores the urgency for new agents. The patent advancement follows a series of significant achievements in 2026, including the granting of U.S. and Japanese composition-of-matter patents for MB-204, the selection of Novotech as the Company's contract research organization for its planned Phase I clinical trial, the securing of non-dilutive funding support from Alberta Innovates, strategic investment participation from 5 Horizons Ventures, and the development of novel pediatric-friendly liquid formulations that may further expand the Company's intellectual property estate. Collectively, these achievements continue to validate Marvel's scientific platform, strengthen its credibility within the biotechnology sector, and support the Company's transition from a pre-clinical organization to a clinical-stage drug development company. 
